Development: Cancer

Based on research published in 2002 the underlying MDT technology seems to identify unique characteristics of drug resistant cancer cells and is rapidly gaining attention as having the potential to offer hope to cancer patients. The early, patented work by Dr. Newell-Rogers has been validated and reinforced by recent research published by other scientists.

Working with several compounds including dichloroacetate (DCA), etomoxir and 2-deoxyglucose (2-DG), we are now working to develop a drug compound and dosing based on MDT for victims of glioblastoma, a particularly deadly brain tumor. Our expectation is that this therapy will be used in conjunction with traditional cancer treatments such as chemotherapy and radiation. The drug's role will be to target the cells capable of surviving those treatments. Drug resistance is the leading cause of death among cancer patients. Our hope is that our new approach may provide novel therapy aimed at dealing with drug resistance.

Viral Genetics has created a wholly owned subsidiary called MetaCytoLytics, Inc., dedicated to advancing new treatments based on MDT.